Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Drugmaker Pfizer Decides Not to Break Up Business

By Tom Murphy AP Health Writer | September 26, 2016

Pfizer will not split into two publicly traded companies, a decision that, at least for now, ends Wall Street speculation over the drugmaker’s future.

The company said Monday it believes it is best positioned to maximize shareholder value in its current form, but it reserves the right to split in the future if the situation changes.

The maker of Viagra and the pain treatment Lyrica has been talking about a split for several years, thinking that two companies might grow faster than one. It had said it would make a decision by the end of this year.

Chances of the breakup actually taking place began to fade over the summer due in part to rising sales for key new drugs from Pfizer and rising prospects for its drugs under development.

Pfizer CEO Ian Read told analysts last month that the prospect of a split was not a “make-or-break decision” for the company.

The company said Monday that a split would not help the competitive positioning of its businesses, and such a move would create disruptions and increased costs.

The drugmaker’s most likely path forward involves hunting for more acquisition targets, according to Bernstein analyst Dr. Tim Anderson.

Pfizer has been buying several companies and products to help make up for a wave of sales losses to cheaper, generic competition, most notably for the cholesterol pill Lipitor. It also attempted and failed at two mega-acquisitions, first of Britain’s AstraZeneca Plc and this year of Ireland’s Allergan Plc.

Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was buying rights to AstraZeneca’s portfolio of approved and experimental antibiotic and antifungal pills.

In June, Pfizer completed a $5.2-billion acquisition of Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

“A critic could argue that Pfizer is back to being the same old Pfizer as before, relying on (mergers and acquisitions) to grow and to refill its pipeline, but at the expense of growing larger in the process depending on the size of deals it chases,” Anderson said in a research note.

Shares of Pfizer Inc., based in New York, slipped 48 cents, or 1.4 percent, to $33.78 in premarket trading Monday. The stock had climbed about 6 percent so far this year, as of Friday.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE